Foundayo Shows Superior Efficacy in Diabetes Treatment Trials
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Newsfilter
- Clinical Trial Results: In the ACHIEVE-3 trial, Foundayo 17.2 mg achieved a 57.1% relative reduction in A1C and a 73.6% greater weight loss compared to oral semaglutide 14 mg, demonstrating significant advantages in diabetes treatment that could redefine care standards.
- Broad Applicability: In ACHIEVE-2 and ACHIEVE-5, up to 68.6% and 69.1% of participants achieved an A1C goal of ≤6.5%, indicating Foundayo's effectiveness across diverse patient populations, thereby enhancing its market competitiveness.
- FDA Submission Plans: Lilly intends to submit Foundayo for FDA approval by the end of Q2, which, if approved, will provide a new oral treatment option for diabetes patients and further expand its product portfolio.
- Safety and Tolerability: Across the three trials, Foundayo demonstrated good safety and tolerability, with common adverse events being gastrointestinal symptoms and lower discontinuation rates compared to oral semaglutide, highlighting its potential for clinical use.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1131.420
Low
950.00
Averages
1192
High
1500
Current: 1131.420
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zealand Pharma's Phase III Trial Results Disappointing
- Disappointing Trial Results: Zealand Pharma's Phase III trial of Survodutide revealed a 19% dropout rate due to adverse effects, causing the company's shares to plummet nearly 23%, indicating a significant impact on its competitiveness in the weight-loss drug market.
- Diminished Competitive Edge: The disappointing results further solidify Eli Lilly and Novo Nordisk's dominance in the GLP-1 market, reducing competitive pressure and helping them maintain market share and pricing power.
- Positive Data for Eli Lilly: At the American Diabetes Association meeting, Eli Lilly presented promising data for Retatrutide, with participants achieving an average weight loss of about 19% and only a 4% dropout rate, indicating an expanding competitive advantage in the weight-loss drug sector.
- Divergent Market Reactions: While Eli Lilly's stock rose approximately 2.5% due to the new data, Novo Nordisk's shares declined amid increasing competition, reflecting a clear divergence in market performance between the two companies.
See More
Eli Lilly's Retatrutide Trial Shows Significant Weight Loss
- Clinical Trial Results: Eli Lilly presented pivotal TRIUMPH-1 study results at the American Diabetes Association meeting, revealing that adults with obesity receiving 12 mg of Retatrutide lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, with 65.3% achieving a BMI below 30 and 33.3% reaching a healthy BMI under 25, indicating significant weight loss efficacy.
- Sustained Weight Loss: In a pre-specified extension for participants with a BMI ≥ 35, the average weight loss sustained over 104 weeks reached 85 pounds (30.3%), demonstrating Retatrutide's long-term effectiveness and potential market competitiveness.
- Multiple Health Benefits: Beyond weight loss, Retatrutide achieved up to 73.1% pain score reduction in knee osteoarthritis patients and a 60.6% reduction in severity for those with moderate-to-severe obstructive sleep apnea, highlighting its potential in addressing obesity-related health issues.
- Cardiometabolic Improvements: In the TRANSCEND-T2D-1 trial, type 2 diabetes participants experienced HbA1c reductions of up to 2.0% and weight loss of 36.6 pounds (16.8%), with triglycerides reduced by up to 41% and systolic blood pressure lowered by 12.3 mmHg, showcasing broad cardiometabolic health benefits of the drug.
See More
Pharmaceutical Stocks Surge, Led by Eli Lilly's Breakout
- Pharma Leadership Strengthens: Pharmaceutical stocks have recently decoupled from the broader market, with Eli Lilly breaking out to all-time highs, which has propelled the iShares U.S. Pharmaceuticals ETF (IHE) to new highs, indicating strong leadership and market confidence in the sector.
- Relative Strength Rebound: The ratio of IHE to the S&P 500 is rebounding off support from its 200-day moving average, suggesting that the pharma sector is poised for continued outperformance in the coming weeks, enhancing investor confidence in this area.
- Strong Technical Signals: Johnson & Johnson's weekly charts indicate signs of an oversold rebound, with improving MACD indicators suggesting the company has the potential to reassert its leadership position within the pharma sector, attracting more investor attention.
- Key Support and Resistance: JNJ's 200-day moving average is around $213, with resistance near $249, and as momentum shifts upward, the risk-reward profile for JNJ is becoming clearer, drawing investor interest.
See More
Foundayo Shows Superior Efficacy in Diabetes Treatment Trials
- Clinical Trial Results: In the ACHIEVE-3 trial, Foundayo 17.2 mg achieved a 57.1% relative reduction in A1C and a 73.6% greater weight loss compared to oral semaglutide 14 mg, demonstrating significant advantages in diabetes treatment that could redefine care standards.
- Patient Target Achievement: In ACHIEVE-2 and ACHIEVE-5, up to 68.6% and 69.1% of participants reached the A1C goal of ≤6.5% with Foundayo, indicating its effectiveness in blood sugar control and potential for widespread clinical adoption.
- FDA Submission Plans: Lilly plans to submit Foundayo for FDA approval by the end of Q2, which, if approved, would provide a new oral treatment option for diabetes patients and further expand its market share.
- Safety and Tolerability: Across the three trials, Foundayo demonstrated good safety and tolerability, with common adverse events being gastrointestinal symptoms and discontinuation rates comparable to existing treatments, highlighting its potential for clinical use.
See More
Foundayo Shows Superior Efficacy in Diabetes Treatment Trials
- Clinical Trial Results: In the ACHIEVE-3 trial, Foundayo 17.2 mg achieved a 57.1% relative reduction in A1C and a 73.6% greater weight loss compared to oral semaglutide 14 mg, demonstrating significant advantages in diabetes treatment that could redefine care standards.
- Broad Applicability: In ACHIEVE-2 and ACHIEVE-5, up to 68.6% and 69.1% of participants achieved an A1C goal of ≤6.5%, indicating Foundayo's effectiveness across diverse patient populations, thereby enhancing its market competitiveness.
- FDA Submission Plans: Lilly intends to submit Foundayo for FDA approval by the end of Q2, which, if approved, will provide a new oral treatment option for diabetes patients and further expand its product portfolio.
- Safety and Tolerability: Across the three trials, Foundayo demonstrated good safety and tolerability, with common adverse events being gastrointestinal symptoms and lower discontinuation rates compared to oral semaglutide, highlighting its potential for clinical use.
See More
US Stocks Rebound Led by Chipmakers Amid Geopolitical Tensions
- Market Rebound: The S&P 500 Index rose by 1.01%, the Dow Jones Industrial Average increased by 0.46%, and the Nasdaq 100 Index climbed by 2.39%, indicating a recovery from last Friday's selloff, particularly driven by strong performances in chipmakers and AI infrastructure stocks.
- Oil Price Volatility: WTI crude oil prices initially surged over 4% due to escalating tensions between Iran and Israel but retreated after Iran announced an end to its military operations, alleviating pressure on the stock market as expectations for a ceasefire emerged.
- Interest Rate Expectations: The market is pricing in only a 3% chance of a 25 basis point rate hike at the next FOMC meeting, reflecting a cautious outlook among investors, especially following robust nonfarm payroll data, which could influence bond market dynamics.
- Tech Stock Surge: Intel's stock surged by 11% after Google placed an order for three million Tensor Processing Units, driving a broader rally in chip stocks, highlighting the tech sector's critical role in the market recovery and potentially attracting more investor interest in related equities.
See More
Zealand Pharma's Phase III Trial Results Disappointing
- Disappointing Trial Results: Zealand Pharma's Phase III trial of Survodutide revealed a 19% dropout rate due to adverse effects, causing the company's shares to plummet nearly 23%, indicating a significant impact on its competitiveness in the weight-loss drug market.
- Diminished Competitive Edge: The disappointing results further solidify Eli Lilly and Novo Nordisk's dominance in the GLP-1 market, reducing competitive pressure and helping them maintain market share and pricing power.
- Positive Data for Eli Lilly: At the American Diabetes Association meeting, Eli Lilly presented promising data for Retatrutide, with participants achieving an average weight loss of about 19% and only a 4% dropout rate, indicating an expanding competitive advantage in the weight-loss drug sector.
- Divergent Market Reactions: While Eli Lilly's stock rose approximately 2.5% due to the new data, Novo Nordisk's shares declined amid increasing competition, reflecting a clear divergence in market performance between the two companies.
See More
Eli Lilly's Retatrutide Trial Shows Significant Weight Loss
- Clinical Trial Results: Eli Lilly presented pivotal TRIUMPH-1 study results at the American Diabetes Association meeting, revealing that adults with obesity receiving 12 mg of Retatrutide lost an average of 70.3 pounds (28.3% of body weight) over 80 weeks, with 65.3% achieving a BMI below 30 and 33.3% reaching a healthy BMI under 25, indicating significant weight loss efficacy.
- Sustained Weight Loss: In a pre-specified extension for participants with a BMI ≥ 35, the average weight loss sustained over 104 weeks reached 85 pounds (30.3%), demonstrating Retatrutide's long-term effectiveness and potential market competitiveness.
- Multiple Health Benefits: Beyond weight loss, Retatrutide achieved up to 73.1% pain score reduction in knee osteoarthritis patients and a 60.6% reduction in severity for those with moderate-to-severe obstructive sleep apnea, highlighting its potential in addressing obesity-related health issues.
- Cardiometabolic Improvements: In the TRANSCEND-T2D-1 trial, type 2 diabetes participants experienced HbA1c reductions of up to 2.0% and weight loss of 36.6 pounds (16.8%), with triglycerides reduced by up to 41% and systolic blood pressure lowered by 12.3 mmHg, showcasing broad cardiometabolic health benefits of the drug.
See More
Pharmaceutical Stocks Surge, Led by Eli Lilly's Breakout
- Pharma Leadership Strengthens: Pharmaceutical stocks have recently decoupled from the broader market, with Eli Lilly breaking out to all-time highs, which has propelled the iShares U.S. Pharmaceuticals ETF (IHE) to new highs, indicating strong leadership and market confidence in the sector.
- Relative Strength Rebound: The ratio of IHE to the S&P 500 is rebounding off support from its 200-day moving average, suggesting that the pharma sector is poised for continued outperformance in the coming weeks, enhancing investor confidence in this area.
- Strong Technical Signals: Johnson & Johnson's weekly charts indicate signs of an oversold rebound, with improving MACD indicators suggesting the company has the potential to reassert its leadership position within the pharma sector, attracting more investor attention.
- Key Support and Resistance: JNJ's 200-day moving average is around $213, with resistance near $249, and as momentum shifts upward, the risk-reward profile for JNJ is becoming clearer, drawing investor interest.
See More
Foundayo Shows Superior Efficacy in Diabetes Treatment Trials
- Clinical Trial Results: In the ACHIEVE-3 trial, Foundayo 17.2 mg achieved a 57.1% relative reduction in A1C and a 73.6% greater weight loss compared to oral semaglutide 14 mg, demonstrating significant advantages in diabetes treatment that could redefine care standards.
- Patient Target Achievement: In ACHIEVE-2 and ACHIEVE-5, up to 68.6% and 69.1% of participants reached the A1C goal of ≤6.5% with Foundayo, indicating its effectiveness in blood sugar control and potential for widespread clinical adoption.
- FDA Submission Plans: Lilly plans to submit Foundayo for FDA approval by the end of Q2, which, if approved, would provide a new oral treatment option for diabetes patients and further expand its market share.
- Safety and Tolerability: Across the three trials, Foundayo demonstrated good safety and tolerability, with common adverse events being gastrointestinal symptoms and discontinuation rates comparable to existing treatments, highlighting its potential for clinical use.
See More
Foundayo Shows Superior Efficacy in Diabetes Treatment Trials
- Clinical Trial Results: In the ACHIEVE-3 trial, Foundayo 17.2 mg achieved a 57.1% relative reduction in A1C and a 73.6% greater weight loss compared to oral semaglutide 14 mg, demonstrating significant advantages in diabetes treatment that could redefine care standards.
- Broad Applicability: In ACHIEVE-2 and ACHIEVE-5, up to 68.6% and 69.1% of participants achieved an A1C goal of ≤6.5%, indicating Foundayo's effectiveness across diverse patient populations, thereby enhancing its market competitiveness.
- FDA Submission Plans: Lilly intends to submit Foundayo for FDA approval by the end of Q2, which, if approved, will provide a new oral treatment option for diabetes patients and further expand its product portfolio.
- Safety and Tolerability: Across the three trials, Foundayo demonstrated good safety and tolerability, with common adverse events being gastrointestinal symptoms and lower discontinuation rates compared to oral semaglutide, highlighting its potential for clinical use.
See More
US Stocks Rebound Led by Chipmakers Amid Geopolitical Tensions
- Market Rebound: The S&P 500 Index rose by 1.01%, the Dow Jones Industrial Average increased by 0.46%, and the Nasdaq 100 Index climbed by 2.39%, indicating a recovery from last Friday's selloff, particularly driven by strong performances in chipmakers and AI infrastructure stocks.
- Oil Price Volatility: WTI crude oil prices initially surged over 4% due to escalating tensions between Iran and Israel but retreated after Iran announced an end to its military operations, alleviating pressure on the stock market as expectations for a ceasefire emerged.
- Interest Rate Expectations: The market is pricing in only a 3% chance of a 25 basis point rate hike at the next FOMC meeting, reflecting a cautious outlook among investors, especially following robust nonfarm payroll data, which could influence bond market dynamics.
- Tech Stock Surge: Intel's stock surged by 11% after Google placed an order for three million Tensor Processing Units, driving a broader rally in chip stocks, highlighting the tech sector's critical role in the market recovery and potentially attracting more investor interest in related equities.
See More
